CLINICAL TRIALS PROFILE FOR NERAMEXANE
✉ Email this page to a colleague
Clinical Trials for Neramexane
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00090116 ↗ | The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease | Completed | Forest Laboratories | Phase 3 | Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist). |
NCT00405886 ↗ | Neramexane for Tinnitus | Completed | Merz Pharmaceuticals GmbH | Phase 2 | Tinnitus is commonly referred to as "ringing of the ears" - the perception of sounds in the absence of an external source of acoustic signals. Tinnitus may represent a severe disease and symptoms include depression, sleeping difficulties, decreased sound tolerance and hearing loss. One hypothesis is that tinnitus is caused by an increased activity of NMDA glutamate and dysfunctional alpha9/alpha10 acetylcholine receptors in the inner ear and central nervous system. Neramexane may alleviate tinnitus symptoms due to its NMDA and alpha9/alpha10 nACh receptor blocking activity. The purpose of this study is to assess the safety and efficacy of Neramexane compared with placebo in patients with subjective tinnitus. |
NCT00661440 ↗ | Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus | Completed | Merz Pharmaceuticals GmbH | Phase 2 | The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only. |
NCT00712283 ↗ | Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers | Completed | Merz Pharmaceuticals GmbH | Phase 1 | Determination of the ability to drive and operate machines after single and multiple oral dose of Neramexane as compared to placebo |
NCT00739635 ↗ | Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus | Completed | Merz Pharmaceuticals GmbH | Phase 3 | The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo. |
NCT00772980 ↗ | Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus | Completed | Merz Pharmaceuticals GmbH | Phase 3 | The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Neramexane
Condition Name
Clinical Trial Locations for Neramexane
Trials by Country
Clinical Trial Progress for Neramexane
Clinical Trial Phase
Clinical Trial Sponsors for Neramexane
Sponsor Name